Skip to content

ProMRI AFFIRM Study of the EVIA/ENTOVIS Pacemaker With Safio S Pacemaker Leads

Master Study for the MRI Compatibility of the EVIA/ENTOVIS Pacemaker in Combination With Safio S Pacemaker Lead

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01460992
Acronym
ProMRIAFFIRM
Enrollment
121
Registered
2011-10-27
Start date
2012-03-31
Completion date
2013-11-30
Last updated
2013-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Disease

Keywords

Pacemaker therapy, Magnetic Resonance Imaging (MRI), EVIA/ENTOVIS

Brief summary

This investigation is designed to demonstrate the clinical safety of the EVIA/ ENTOVIS pacemaker system when used under specific MRI conditions.

Detailed description

In the past, MR scans were always contraindicated for pacemaker patients. If particular prerequisites and conditions are fulfilled, MR scans can now be conducted on patients with BIOTRONIK's EVIA/ENTOVIS pacemakers in combination with the Safio S pacemaker leads, scheduled to be part of this clinical study. The specific MRI conditions for this investigation with the EVIA/ENTOVIS pacemaker family and Safio S pacemaker leads are defined in the study protocol

Interventions

PROCEDUREEvia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions

patients will undergo an MRI scan for 30 minutes.

Sponsors

Biotronik SE & Co. KG
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pacemaker system consisting solely of the EVIA/ENTOVIS pacemaker and Safio S pacemaker leads * The pacemaker system has to be implanted, repositioned or exchanged at least 5 weeks prior to enrollment * Age more than 18 years * Understand the nature of the procedure * Able and willing to complete MRI testing * Able and willing to activate and use the Cardio Messenger * Give written informed consent * Able to complete all testing required by the clinical protocol * Ability to measure atrial and/or ventricular pacing threshold(s)\* (at 0.4 ms) * All pacing thresholds do not exceed 2.0V @0.4ms. * Available for follow-up visit at the investigational site * Patient body height greater or equal to 140 cm * Pectoral implantation * The ascertained lead impedance is between 200 and 1500 Ohms.

Exclusion criteria

* No EVIA/ENTOVIS /Safio S pacemaker system implanted * Pacing threshold(s) (at 0.4 ms) and sensing amplitudes are not measurable * Meet one or more of the contraindications * Being pregnant * Have a life expectancy of less than three months * Cardiac surgery already scheduled in the next three months * Enrolled in another cardiac clinical investigation * Have other medical implants that may interact with MRI, e.g. abandoned pacemaker/ICD leads, lead extensions, other active medical devices, non-MRI compatible devices (e.g. mechanical tricuspid valve) * Have other metallic artifacts/components in body that may interact with MRI

Design outcomes

Primary

MeasureTime frameDescription
Primary hypothesis 1: MRI and pacing system related Serious Adverse Device Effect (SADE) free rate3 monthsMRI and pacing system related Serious Adverse Device Effect (SADE) Free-Rate is greater than 90%.
Primary hypotheses 2 and 3: pacing threshold rise (atrial and ventricular)1 monthThe atrial or ventricular MRI induced pacing threshold rise is not larger than or equal to 0.5 V between Pre-MRI and 1-month follow-up
Primary hypothesis 4: P-wave sensing attenuation1 monthP-wave attenuation: P-wave amplitude decrease (between pre-MRI follow-up and 1-month follow-up) exceeding 50% or a P-wave amplitude at 1-month follow-up smaller or equal to 1.5 mV
Primary hypothesis 5: R-wave sensing attenuation1 monthR-wave attenuation: R-wave amplitude decrease (between pre-MRI follow-up and 1-month follow-up) exceeding 50% or a R-wave amplitude at 1-month follow-up smaller or equal to 5.0 mV.

Countries

Austria, Czechia, Germany, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026